Kyowa Kirin Co., Ltd.
Financial Summary Supplemental Material – Fiscal Year Ending December 2025 –
For the fiscal year ending December 2025, revenue was 496.8 billion yen, flat year-over-year, core operating income was 127.9 billion yen, down 4% year-over-year, and net income attributable to owners of parent was 67.0 billion yen, up 12% year-over-year.
Key Figures
- Revenue: 496.8 billion yen (Fiscal Year Ending December 2025 Results, 0% increase YoY)
- Core Operating Income: 127.9 billion yen (Fiscal Year Ending December 2025 Results, 4% decrease YoY)
- Net Income Attributable to Owners of Parent (Quarterly): 67.0 billion yen (Fiscal Year Ending December 2025 Results, 12% increase YoY)
AI要約
Business Overview
Kyowa Kirin Co., Ltd.'s consolidated performance for the fiscal year ending December 2025 showed revenue of 496.8 billion yen, nearly flat year-over-year. Core operating income was 127.9 billion yen, down 4% year-over-year; however, net income attributable to owners of parent increased 12% to 67.0 billion yen. Research and development expenses were 101.2 billion yen, down 2% YoY, with an R&D expense ratio of 20.4%. The overseas sales ratio rose to 74%, reflecting progress in global expansion. Sales of key products were strong, with Crysvita achieving 216.4 billion yen (9% increase YoY) and Poteligeo recording 45.7 billion yen (20% increase YoY).
Outlook and Development Pipeline
For 2026, revenue is forecast at 520.0 billion yen (5% increase YoY) and core operating income at 129.0 billion yen (1% increase YoY). Capital expenditures are planned at 33.9 billion yen, and intangible asset investments at 18.3 billion yen. The development pipeline includes multiple global development products such as ziftomenib (KOMZIFTI) and KHK4083/AMG 451 (locatinlimab). In September 2025, following the termination of the collaboration agreement with Amgen Inc., rights to KHK4083 were reacquired. These new drug developments are expected to drive future growth.
